Ovid Therapeutics Inc. Research And Development Expense

• Ovid Therapeutics Inc. showed a decrease of -30.4% in Research And Development Expense from 2024 to 2025.
• This data is from Ovid Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 11 years of available data (2015 to 2025), Ovid Therapeutics Inc.'s Research And Development Expense has grown by 286.9%.
• Historical annual values: Fiscal year 2025: $25.58 million | Fiscal year 2024: $36.77 million | Fiscal year 2023: $28.59 million | Fiscal year 2022: $24.62 million | Fiscal year 2021: $46.94 million | Fiscal year 2020: $63.42 million | Fiscal year 2019: $42.16 million | Fiscal year 2018: $33.79 million | Fiscal year 2017: $49.97 million | Fiscal year 2016: $9.59 million | Fiscal year 2015: $6.61 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026